New studies start to pinpoint the best strategy for treating HER2-positive breast cancer before surgery and lay the groundwork for future clinical trials. 

"/>
ADVERTISEMENT

Drug Combo Tames HER2-Positive Breast Cancer

New studies start to pinpoint the best strategy for treating HER2-positive breast cancer before surgery and lay the groundwork for future clinical trials. 

BY MELISSA WEBER
PUBLISHED THURSDAY, DECEMBER 9, 2010
Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
Treatment for HER2-positive breast cancer turned a corner more than a decade ago with the approval of Herceptin (trastuzumab). More recently, another successful drug called Tykerb (lapatinib) hit the market. The question then became whether Herceptin, Tykerb or a combination of the two would be most effective in stifling the aggressive disease. Two studies presented at the San Antonio Breast Cancer Symposium offer some clues.

In the first study, nicknamed NeoALTTO, a combination of Tykerb, Herceptin and the chemotherapy drug Taxol (paclitaxel) outdid either targeted agent alone. Among 455 patients with HER2-positive breast cancer, giving the three-drug combo before surgery—known as neoadjuvant therapy—resulted in half of patients seeing cancer cells disappear completely in the breast at the time of surgery. The same pathological complete response was seen in only 30 percent of women receiving Herceptin alone, and 25 percent for Tykerb alone. Serious side effects were more common in the Tykerb-alone arm and included diarrhea, liver function problems, low white blood cell counts and rash. Although heart damage has been associated with HER2-targeted drugs, no patients experienced toxic effects to the heart at the time of surgery, researchers reported.

Similarly, investigators in the GeparQuinto study wanted to know which of the HER2-targeted drugs was more effective when given before surgery. In a head-to-head comparison, 620 women with HER2-positive disease received chemotherapy (epirubicin and cyclophosphamide followed by Taxotere [docetaxel]) plus either Herceptin or Tykerb. Like the NeoALTTO results, Herceptin edged out Tykerb when added to chemotherapy. No cancer cells were detected in the breast or lymph nodes at the time of surgery in 31 percent of patients on Herceptin compared with 22 percent receiving Tykerb. Serious cases of diarrhea and low white blood cell counts were seen in the Tykerb arm of the study.

Investigators of both studies will follow patients to see whether the absence of cancer cells at the time of surgery results in longer survival.

The HER2-targeted drug combo also works in combating advanced breast cancer. Last year in San Antonio, researchers reported that combining Herceptin and Tykerb helped women with heavily pretreated metastatic disease live approximately 4.5 months longer than Tykerb alone.

Excessive amounts of the HER2 protein cause cancer cells to grow more rapidly—a scenario associated with 20 to 25 percent of all breast cancers. Herceptin, approved for both early-stage and advanced cancers, targets the HER2 protein on the outside of cancer cells. Tykerb, currently approved only for advanced HER2-positive breast cancer, enters the cancer cell and blocks HER2—as well as growth signals from another protein called HER1—from inside the cell. Combining the two drugs could essentially knock out the cancer cell with a double blow.

While the studies were very encouraging, they’re not ready for use outside a clinical trial, said Eric Winer, MD, chief of the division of women’s cancers at Dana-Farber Cancer Institute in Boston. “We’ve been misled too often with early results. And while on the one hand we want to bring the best treatments to people as soon as possible, on the other hand, we have to have some greater assurance that they’re really having a meaningful effect.” 

Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
ADVERTISEMENT
Cure Connections
Related Articles
Living With Stage 4 Breast Cancer: My Semi-Charmed Kind of Life
I led a fairly charmed life up until about the age of 29. Life just always seemed to work out for me. I was the gal who had a flat tire 100 yards from the tire shop.
MRI Would Rather Not, Thank You
Male breast cancer survivor discusses a few uncertainties about his first MRI.
Healing in the Key of C: Joy in Music for Cancer Survivors
BY KHEVIN BARNES
The discord of our cancer is only a wrong note in our expression of the score of life. And I believe that, with due diligence and conscious camaraderie with our own bodies, we can live in harmony once more.
It Gets Better After the Shock of an Initial Cancer Diagnosis
A breast cancer and melanoma survivor testifies that her life got better again after hearing she had cancer.
Cancer Should Never Be a Usual Experience
I have a "usually" when it comes to cancer? How could anything ever be usual about cancer? Am I nuts?
Related Videos
Hope Rugo on Managing Sexual Dysfunction From Ovarian Suppression
BY HOPE S. RUGO
Hope S. Rugo discusses managing sexual dysfunction from ovarian suppression treatment for breast cancer.
Hope Rugo on Managing Effects From Ovarian Suppression in Patients With Breast Cancer
BY HOPE S. RUGO
Hope S. Rugo discusses managing effects from ovarian suppression treatment for breast cancer.
Kara Maxwell Explains Breast Cancer Clinical Trials
BY KARA MAXWELL
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, explains how a breast cancer clinical trial works.
Kara Maxwell Provides Advice for a Patient With Early Stage Breast Cancer
BY KARA MAXWELL
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, provides advice for a patient with early stage breast cancer.
Jennifer Klemp on Survivorship for Patients With Hereditary Breast Cancer
BY JENNIFER KLEMP, PHD, MPH
Jennifer Klemp, PhD, MPH, director, Breast Cancer Survivorship Center, The University of Kansas Cancer Center, discusses survivorship for patients with hereditary breast cancer.
$auto_registration$